These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 37813754)
1. Cancer therapy with iRGD as a tumor-penetrating peptide. Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754 [TBL] [Abstract][Full Text] [Related]
2. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers. Zuo H J Oncol; 2019; 2019():9367845. PubMed ID: 31346334 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis. Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702 [TBL] [Abstract][Full Text] [Related]
4. iRGD as a tumor‑penetrating peptide for cancer therapy (Review). Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432 [TBL] [Abstract][Full Text] [Related]
5. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394 [TBL] [Abstract][Full Text] [Related]
6. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL? Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869 [TBL] [Abstract][Full Text] [Related]
7. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging. Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354 [TBL] [Abstract][Full Text] [Related]
8. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Kang S; Lee S; Park S Polymers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847045 [TBL] [Abstract][Full Text] [Related]
9. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669 [TBL] [Abstract][Full Text] [Related]
10. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment. Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868 [TBL] [Abstract][Full Text] [Related]
11. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. Lao X; Liu M; Chen J; Zheng H PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262 [TBL] [Abstract][Full Text] [Related]
12. Increased antitumor activity of tumor-specific peptide modified thymopentin. Lao X; Li B; Liu M; Chen J; Gao X; Zheng H Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer. He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861 [TBL] [Abstract][Full Text] [Related]
14. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Hu C; Huang Y; Chen Y Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418 [TBL] [Abstract][Full Text] [Related]
15. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice. Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766 [TBL] [Abstract][Full Text] [Related]
16. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy. Cho HJ; Park SJ; Lee YS; Kim S J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135 [TBL] [Abstract][Full Text] [Related]
17. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide. E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024 [TBL] [Abstract][Full Text] [Related]
18. De novo design of a tumor-penetrating peptide. Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901 [TBL] [Abstract][Full Text] [Related]